BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance

BRCA1 mutant carcinomas are sensitive to PARP inhibitor (PARPi) therapy; however, resistance arises. BRCA1 BRCT domain mutant proteins do not fold correctly and are subject to proteasomal degradation, resulting in PARPi sensitivity. In this study, we show that cell lines and patient-derived tumors,...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yifan, Bernhardy, Andrea J., Nacson, Joseph, Krais, John J., Tan, Yin-Fei, Nicolas, Emmanuelle, Radke, Marc R., Handorf, Elizabeth, Llop-Guevara, Alba, Balmaña, Judith, Swisher, Elizabeth M., Serra, Violeta, Peri, Suraj, Johnson, Neil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906494/
https://www.ncbi.nlm.nih.gov/pubmed/31827092
http://dx.doi.org/10.1038/s41467-019-13530-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906494/
https://www.ncbi.nlm.nih.gov/pubmed/31827092
http://dx.doi.org/10.1038/s41467-019-13530-6

Ejemplares similares